Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $0.06.

  • Amicus Therapeutics' EPS (Basic) rose 40000.0% to $0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.04, marking a year-over-year increase of 8823.53%. This contributed to the annual value of -$0.18 for FY2024, which is 6385.72% up from last year.
  • Latest data reveals that Amicus Therapeutics reported EPS (Basic) of $0.06 as of Q3 2025, which was up 40000.0% from -$0.08 recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' EPS (Basic) peaked at $0.06 during Q3 2025, and registered a low of -$0.31 during Q4 2021.
  • For the 5-year period, Amicus Therapeutics' EPS (Basic) averaged around -$0.12, with its median value being -$0.11 (2023).
  • Over the last 5 years, Amicus Therapeutics' EPS (Basic) had its largest YoY gain of 40000.0% in 2025, and its largest YoY loss of 6000.0% in 2025.
  • Over the past 5 years, Amicus Therapeutics' EPS (Basic) (Quarter) stood at -$0.31 in 2021, then surged by 37.01% to -$0.19 in 2022, then surged by 43.08% to -$0.11 in 2023, then soared by 144.02% to $0.05 in 2024, then grew by 23.91% to $0.06 in 2025.
  • Its last three reported values are $0.06 in Q3 2025, -$0.08 for Q2 2025, and -$0.07 during Q1 2025.